These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34876446)

  • 1. Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid.
    Howell P; Upton C; Mvuna N; Olugbosi M
    BMJ Case Rep; 2021 Dec; 14(12):. PubMed ID: 34876446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
    Gomez GB; Siapka M; Conradie F; Ndjeka N; Garfin AMC; Lomtadze N; Avaliani Z; Kiria N; Malhotra S; Cook-Scalise S; Juneja S; Everitt D; Spigelman M; Vassall A
    BMJ Open; 2021 Dec; 11(12):e051521. PubMed ID: 34862287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe.
    Günther G; Guglielmetti L; Kherabi Y; Duarte R; Lange C;
    Clin Microbiol Infect; 2024 Sep; 30(9):1197.e1-1197.e4. PubMed ID: 38490355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis.
    Mulder C; Rupert S; Setiawan E; Mambetova E; Edo P; Sugiharto J; Useni S; Malhotra S; Cook-Scalise S; Pambudi I; Kadyrov A; Lawanson A; van den Hof S; Gebhard A; Juneja S; Sohn H
    BMJ Glob Health; 2022 Jan; 7(1):. PubMed ID: 34992077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts.
    Oelofse S; Esmail A; Diacon AH; Conradie F; Olayanju O; Ngubane N; Howell P; Everitt D; Crook AM; Mendel CM; Wills GH; Olugbosi M; Del Parigi A; Sun E; Calatroni A; Spigelman M; Dheda K
    Int J Tuberc Lung Dis; 2021 Jun; 25(6):453-460. PubMed ID: 34049607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of MDR, Pre-XDR, XDR, and Rifampicin-Resistant Tuberculosis or in Case of Intolerance to at Least Rifampicin in Austria, Germany, and Switzerland.
    Otto-Knapp R; Bauer T; Brinkmann F; Feiterna-Sperling C; Friesen I; Geerdes-Fenge H; Hartmann P; Häcker B; Heyckendorf J; Kuhns M; Lange C; Maurer FP; Nienhaus A; Priwitzer M; Richter E; Salzer HJF; Schoch OD; Schönfeld N; Schaberg T
    Respiration; 2024; 103(9):593-600. PubMed ID: 38810608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
    Conradie F; Bagdasaryan TR; Borisov S; Howell P; Mikiashvili L; Ngubane N; Samoilova A; Skornykova S; Tudor E; Variava E; Yablonskiy P; Everitt D; Wills GH; Sun E; Olugbosi M; Egizi E; Li M; Holsta A; Timm J; Bateson A; Crook AM; Fabiane SM; Hunt R; McHugh TD; Tweed CD; Foraida S; Mendel CM; Spigelman M;
    N Engl J Med; 2022 Sep; 387(9):810-823. PubMed ID: 36053506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis.
    Hasan T; Medcalf E; Nyang'wa BT; Egizi E; Berry C; Dodd M; Foraida S; Gegia M; Li M; Mirzayev F; Morgan H; Motta I; Nguyen L; Schumacher S; Schlub T; Fox G
    Clin Infect Dis; 2024 Mar; 78(3):730-741. PubMed ID: 37874021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.
    Borisov SE; Dheda K; Enwerem M; Romero Leyet R; D'Ambrosio L; Centis R; Sotgiu G; Tiberi S; Alffenaar JW; Maryandyshev A; Belilovski E; Ganatra S; Skrahina A; Akkerman O; Aleksa A; Amale R; Artsukevich J; Bruchfeld J; Caminero JA; Carpena Martinez I; Codecasa L; Dalcolmo M; Denholm J; Douglas P; Duarte R; Esmail A; Fadul M; Filippov A; Davies Forsman L; Gaga M; Garcia-Fuertes JA; García-García JM; Gualano G; Jonsson J; Kunst H; Lau JS; Lazaro Mastrapa B; Teran Troya JL; Manga S; Manika K; González Montaner P; Mullerpattan J; Oelofse S; Ortelli M; Palmero DJ; Palmieri F; Papalia A; Papavasileiou A; Payen MC; Pontali E; Robalo Cordeiro C; Saderi L; Sadutshang TD; Sanukevich T; Solodovnikova V; Spanevello A; Topgyal S; Toscanini F; Tramontana AR; Udwadia ZF; Viggiani P; White V; Zumla A; Migliori GB
    Eur Respir J; 2017 May; 49(5):. PubMed ID: 28529205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
    Pym AS; Diacon AH; Tang SJ; Conradie F; Danilovits M; Chuchottaworn C; Vasilyeva I; Andries K; Bakare N; De Marez T; Haxaire-Theeuwes M; Lounis N; Meyvisch P; Van Baelen B; van Heeswijk RP; Dannemann B;
    Eur Respir J; 2016 Feb; 47(2):564-74. PubMed ID: 26647431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Dynamic Efficacy Endpoints of the Nix-TB Trial.
    Solans BP; Imperial MZ; Olugbosi M; Savic RM
    Clin Infect Dis; 2023 Jun; 76(11):1903-1910. PubMed ID: 36804834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?
    Dheda K; Cox H; Esmail A; Wasserman S; Chang KC; Lange C
    Respirology; 2018 Jan; 23(1):36-45. PubMed ID: 28850767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Modified BPaL Regimen for Tuberculosis Treatment replaces Linezolid with Inhaled Spectinamides.
    Ali MZ; Dutt TS; MacNeill A; Walz A; Pearce C; Lam H; Philp J; Patterson J; Henao-Tamayo M; Lee RE; Liu J; Robertson GT; Hickey AJ; Meibohm B; Gonzalez-Juarrero M
    bioRxiv; 2024 Jun; ():. PubMed ID: 38014249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis.
    Xu J; Li SY; Almeida DV; Tasneen R; Barnes-Boyle K; Converse PJ; Upton AM; Mdluli K; Fotouhi N; Nuermberger EL
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30833432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model.
    Li SY; Converse PJ; Betoudji F; Lee J; Mdluli K; Upton A; Fotouhi N; Nuermberger EL
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0003523. PubMed ID: 36920217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States.
    Haley CA; Macias P; Jasuja S; Jones BA; Rowlinson MC; Jaimon R; Onderko P; Darnall E; Gomez ME; Peloquin C; Ashkin D; Goswami ND
    Emerg Infect Dis; 2021 Jan; 27(1):332-4. PubMed ID: 33227229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic
    Mota F; Ruiz-Bedoya CA; Tucker EW; Holt DP; De Jesus P; Lodge MA; Erice C; Chen X; Bahr M; Flavahan K; Kim J; Brosnan MK; Ordonez AA; Peloquin CA; Dannals RF; Jain SK
    Nat Commun; 2022 Dec; 13(1):7974. PubMed ID: 36581633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A four-drug standardized short regimen for highly resistant TB in South-West Nigeria.
    Fadeyi MO; Decroo T; Ortuño-Gutiérrez N; Ahmed B; Jinadu A; El-Tayeb O; Adebola W; Kehinde A; Lynen L; Gils T
    Int Health; 2024 Jan; 16(1):123-125. PubMed ID: 37026448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of MDR, pre-XDR, XDR and rifampicin resistant tuberculosis or in case of intolerance to at least rifampicin in Austria, Germany and Switzerland - Amendment dated 19.09.2023 to the Sk2-Guideline: Tuberculosis in adulthood of the German Central Committee against Tuberculosis (DZK) on behalf of the German Respiratory Society (DGP)].
    Otto-Knapp R; Bauer T; Brinkmann F; Feiterna-Sperling C; Friesen I; Geerdes-Fenge H; Hartmann P; Häcker B; Hauer B; Haas W; Heyckendorf J; Kuhns M; Lange C; Maurer FP; Nienhaus A; Priwitzer M; Richter E; Salzer HJF; Schoch O; Schönfeld N; Schaberg T
    Pneumologie; 2024 Jan; 78(1):35-46. PubMed ID: 37931778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of drug resistantTB in patients with HIV co-infection.
    Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
    Expert Opin Pharmacother; 2015; 16(18):2737-50. PubMed ID: 26478945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.